CHF Solutions Inc diskutieren
CHF Solutions Inc
WKN: A2H5Q7 / Name: CHF Solutions / Aktie / Ausrüstung & Versorgung / Small Cap /
-
-
Healthcare | Medical Appliances & Equipment | USA
medical
(Zielkurs erreicht)
Gesundheit | Medizinische Geräte und Ausstattungen | Vereinigte Staaten
a +
(Laufzeit überschritten)
SecteurEquipement et technologie médicale avancés Agenda 31/10 Publication de résultats
CHF Solutions, Inc. est une société de dispositifs médicaux qui fournit des produits pour le traitement de la surcharge liquidienne spécifique aux maladies cardiaques et coronariennes.
Elle participe au développement, à la fabrication et à la commercialisation du système Aquadex FlexFlow, qui fournit un traitement par ultrafiltration aux patients ayant échoué à un traitement diurétique et nécessite une hospitalisation.
La société a été fondée par Crispin Marsh et William S. Peters en novembre 1999 et a son siège à Eden Prairie, dans le Minnesota.
Nombre d'employés : 46 personnes.
(Vom Mitglied beendet)
Der Zytokinsturm ist eine fatale Entgleisung des Immunsystems und wohl die hautsächliche Todesursache in schweren Covid-19 Verläufen bei jüngeren Menschen. Gerüchten zufolge haben einige Kliniken in den USA den Zytokinsturm erfolgreich mit der Aquadex Flüssigkeitsmanagement Technologie von CHF Solutions behandelt. Sollte da was dran sein, haben wir hier plötzlich einen Blockbuster. Ich kann mir vorstellen, das FMC oder Baxter sich den Laden für vergleichsweise kleines Geld (Markkapitalisierung: knapp 30 Mio $, keine Schulden, allerdings eine üble Historie an Kursverwässerung) unter den Nagel reißen werden. Ich denke, hier kann man mal mit zocken…
Ein Satz aus dem QT-Bericht vom 4. August deutet an, das an dem Gerücht zur Zytokinsturm-Behandlung wirklich etwas dran sein könnte: " Submitted a patent application for an adaptation of Aquadex SmartFlow™ system to rapidly clear cytokines." Das wäre ein game-changer!
CHF Solutions’ Physician-Led Webinar Concludes Fluid Overloaded Heart Failure Patients Benefit from Ultrafiltration
September 10, 2020 09:15 ET | Source: CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar, where Dr. John L. Jefferies discussed the use of precision medicine for the treatment of fluid overload in heart failure (HF) patients, including alternatives to diuretics, such as ultrafiltration using the Aquadex SmartFlow™ system.
Clinically important observations made by Dr. Jefferies during the webinar include:
- The impact of fluid overload on HF patients is significant. 90% of HF hospitalizations are due to signs and symptoms of fluid overload.1
- Common fluid overload treatment approaches such as diuretics are associated with mixed outcomes and adverse events. Studies have shown 42% of acutely decompensated HF patients either return to the emergency room, are re-hospitalized or die within 60 days of hospital discharge, regardless of diuretic strategy.2
- Ultrafiltration is an effective treatment strategy for patients with HF. When compared to diuretics, there is a 53% reduction in the risk of rehospitalization among HF patients receiving ultrafiltration.3
- The use of ultrafiltration after cardiac surgery has been shown to improve cardiac performance, 4 reduce the duration of assisted ventilation5 and can reduce the need for blood transfusions.6
“Ultrafiltration has continued to demonstrate efficacy in various clinical settings, and heart failure is a significant area where Aquadex™ has proven to be advantageous in the delivery of effective patient care,” said John Erb, CEO of CHF Solutions. “Dr. Jefferies’ experience provides valuable insights for heart failure clinicians and beyond. There are many patients who can benefit from ultrafiltration therapy and this educational webinar helps to ensure providers are equipped with knowledge of various treatment options for fluid overloaded patients.”
Dr. Jefferies also discussed Aquadex-specific considerations and recommendations in regard to venous access, anticoagulation, ultrafiltration rate and Hematocrit (HCT) and SV02 monitoring. Access this information and a white paper analysis by watching the webinar replay available on the company website and on CHF Solutions’ YouTube page. Dr. Jefferies’ presentation will be a part of the company’s offerings at the 24th Annual Scientific Meeting of the Heart Failure Society October 3-5, 2020.
Dr. Jefferies serves as Director of the Methodist University of Tennessee Cardiovascular Institute. He is a Professor of Pediatric Cardiology, Professor of Preventive Medicine, and a Research Member of St. Jude Children’s Research Hospital. Dr. Jefferies has published 200 peer-reviewed manuscripts and is the Lead Editor for two widely acclaimed textbooks.
Quelle: GlobeNewswire
Buy mit Kursziel 0,0
Kursziel geändert auf 10,0
Neueste Beiträge
Snowman in DWS Group diskutieren